{
    "2019-06-13": [
        [
            {
                "time": "2023-03-15",
                "original_text": "Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Biogen",
                        "Gilead",
                        "Novo Nordisk",
                        "M&A",
                        "Moody’s",
                        "high capacity"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Xeljanz",
                        "Monotherapy",
                        "RA Study",
                        "Effective"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}